Key Highlights

  • Pattern Group's second-quarter Revenue reached about $877 million, up 47% year over year, with management raising full-year 2026 guidance to $3.42 billion to $3.46 billion.
  • PayPay priced its Nasdaq IPO at $16.00 per American depositary share on March 11, 2026, raising roughly $880 million, with SoftBank entities retaining about 91.78% of voting power.
  • Korsana Biosciences reached Nasdaq through a Reverse merger that closed September 8, 2026, including a 1-for-7 Reverse Stock Split and a $380 million private placement.
  • Obook Holdings' OwlPay Harbor payment Volume nearly tripled month over month in August 2026 toward an annualized run-rate around $130 million, even as the company posted a $31.85 million net loss for 2025.

Group any five freshly listed tickers under one theme and the temptation is to smooth over the differences. That would be a mistake here. All five names below trade on Nasdaq and can be verified through primary company disclosures, but they do not share a sector. Two of them, Pattern Group and Obook Holdings, fit a broad Business and commercial services reading reasonably well, because both sell technology-enabled services to other businesses.

PayPay sits in consumer payments and fintech, adjacent to commercial services rather than inside it. Polaryx Therapeutics and Korsana Biosciences are clinical-stage biotech companies with no claim to the services label at all. Pattern Group (NASDAQ:PTRN), Polaryx Therapeutics (NASDAQ:PLYX), PayPay (NASDAQ:PAYP), Korsana Biosciences (NASDAQ:KRSA) and Obook Holdings (NASDAQ:OWLS) are covered honestly, with the mismatches flagged rather than smoothed over.

The Backdrop: A Crowded Class of 2025-26 Debutants

The past twelve months brought a wave of listings across direct listings, traditional IPOs and reverse mergers, and the five tickers here span every one of those routes. Pattern Group came public through a conventional September 2025 IPO. Polaryx and Obook chose direct listings. PayPay ran a large underwritten offering in March 2026. Korsana reached Nasdaq through a reverse merger with a shell-like listed biotech.

That variety matters because listing mechanics shape the risks. Direct listings can produce violent early price swings on thin float. Reverse mergers often arrive with reverse stock splits and concentrated insider ownership. Large sponsor-backed IPOs can leave a dominant parent holding most of the votes.

Pattern Group (NASDAQ:PTRN): The Clearest Commercial-Services Fit

Pattern Group Inc. is the name on this list that most convincingly sits in business and commercial services. It operates as an E-commerce accelerator, using proprietary technology to help consumer brands sell across online marketplaces, and it purchases inventory from Brand partners to sell directly to shoppers across categories such as health and wellness, beauty, home goods and electronics.

Pattern completed its IPO on September 19, 2025. In results released on August 5, 2026, the company reported second-quarter revenue of about $877 million, up 47% year over year, Net Income of roughly $27 million, Diluted Earnings per Share of $0.15 and adjusted EBITDA near $54 million. Management said it raised full-year 2026 guidance to revenue of $3.42 billion to $3.46 billion. Reported net revenue retention was 129%, with a cash position around $346 million and no debt.

Growth and stated profitability set Pattern apart from the pre-revenue names here. Forecast risk centers on marketplace concentration and consumer demand.

Polaryx Therapeutics (NASDAQ:PLYX): A Biotech, Not a Services Name

Polaryx Therapeutics, Inc. does not belong in a business-services basket, and that should be stated plainly. It is a clinical-stage biotechnology company founded in 2014, focused on rare pediatric lysosomal storage disorders. Its lead candidate, PLX-200, is being studied in the SOTERIA Phase 2 trial across conditions including CLN2, CLN3, Krabbe disease and Sandhoff disease.

Polaryx began trading on the Nasdaq Capital Market through a direct listing on February 2, 2026. Direct listings do not raise fresh primary capital at the moment of listing and can trade erratically on limited float, consistent with the wide 52-week range the stock has shown.

As a clinical-stage developer, Polaryx carries the standard binary profile, where value hinges on trial readouts and regulatory steps rather than on revenue. Any near-term catalyst would come from PLX-200 clinical progress, not commercial traction.

PayPay (NASDAQ:PAYP): Fintech and Payments, Adjacent at Best

PayPay Corporation is Japan's dominant QR-code mobile payment operator, backed by SoftBank. It priced its Nasdaq initial public offering at $16.00 per American depositary share on March 11, 2026, with first trading on March 12, 2026. The deal covered 55 million ADSs and raised roughly $880 million, split between PayPay and a SoftBank Vision Fund II affiliate. The stock closed its first session around $18.16.

For the twelve months ended December 31, 2025, PayPay reported net income of about $750.3 million on revenue near $2.33 billion. SoftBank entities retained roughly 91.78% of voting power after the offering.

PayPay is a consumer payments and fintech story, adjacent to commercial services but not a pure business-services vendor. Its reported profitability is unusual for a recent listing. The obvious structural risk is the concentrated SoftBank voting control, which limits minority-shareholder influence.

Korsana Biosciences (NASDAQ:KRSA): A Brand-New De-SPAC Biotech

Korsana Biosciences, Inc. is another clinical-stage biotechnology company, not a services business. It focuses on neurodegenerative disease, led by KRSA-028, an investigational shuttled antibody targeting amyloid Beta for Alzheimer's disease, built on its THETA brain-delivery platform.

Korsana reached Nasdaq through a reverse merger with Cyclerion Therapeutics that closed on September 8, 2026, with shares beginning to trade on the Nasdaq Capital Market on September 9, 2026. The transaction included a 1-for-7 reverse stock split by the predecessor company and a $380 million private Placement led by Fairmount and Venrock Healthcare Capital Partners. Roughly 55.1 million shares and equivalents were outstanding afterward, and management projected the cash to fund operations through 2029.

The reverse split and the sizable insider-heavy financing are classic reverse-merger features, and the science is early. As with Polaryx, the honest note is that this is a biotech placed on a services-labeled list.

Obook Holdings (NASDAQ:OWLS): A Fintech-Services Debutant

Obook Holdings Inc., the listed entity for Taiwan's OwlTing Group, is the second name that fits a business and commercial services reading. It describes itself as a Blockchain Technology company spanning fintech, e-commerce, hospitality and cross-border payments, with a flagship stablecoin-enabled payments platform, OwlPay.

Obook secured a direct listing on Nasdaq in mid-October 2025. For 2025 it reported revenue of about $7.86 million, up roughly 4%, and a net loss near $31.85 million. Aggregated data in early September 2026 put its market Capitalization around $484 million on roughly 88 million shares. The company said its OwlPay Harbor payment volume nearly tripled month over month in August 2026 toward an annualized run-rate around $130 million, and that it added Ohio's money-transmitter license to reach 42 states.

This is a small, loss-making services company where the story is payment-volume scaling against a heavy net loss. Whether run-rate momentum converts into revenue and narrower losses is the key thing to watch.

What Investors Should Watch

The single most useful lens across these five is structure over story. Pattern Group and Obook are the only genuine business-services operators, and they are at opposite ends of maturity. PayPay is a large, profitable consumer-payments company whose main caveat is near-total voting control by SoftBank. Polaryx and Korsana are clinical-stage biotechs whose fortunes turn on trials, not customers. Three mechanical flags deserve ongoing attention: reverse-split history, float and Volatility from direct listings, and insider and sponsor concentration.

The Sector Framing, Not the Tickers

The headline groups PTRN, PLYX, PAYP, KRSA and OWLS as business and commercial services candidates, and the honest verdict is that the label only stretches to fit two of them cleanly. Pattern Group is the strongest services fit and the only clearly profitable, guidance-raising operator. Obook Holdings is a legitimate but very small fintech-services debutant still deep in losses. PayPay is a profitable payments company adjacent to the theme, encumbered by concentrated control. Polaryx and Korsana are clinical-stage biotechs that do not belong under a services banner at all, whatever their individual merits.